{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=3",
    "query": {
      "intervention": "Pharmacodynamics",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 3443,
    "total_pages": 345,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T16:45:26.620Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00907998",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronary Heart Disease"
      ],
      "interventions": [
        {
          "name": "APL180",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 104,
      "start_date": "2009-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-11-20",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 3,
      "location_summary": "Anniston, Alabama • Philadelphia, Pennsylvania • San Antonio, Texas",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00907998"
    },
    {
      "nct_id": "NCT03929744",
      "title": "A Study of LY3502970 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3502970",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 133,
      "start_date": "2019-06-12",
      "completion_date": "2020-11-02",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03929744"
    },
    {
      "nct_id": "NCT00865904",
      "title": "Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-809",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2009-03",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2015-08-28",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865904"
    },
    {
      "nct_id": "NCT02287909",
      "title": "Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 87,
      "start_date": "2014-12",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287909"
    },
    {
      "nct_id": "NCT00637338",
      "title": "Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PF-04603629",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2008-04",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-07-31",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00637338"
    },
    {
      "nct_id": "NCT07051629",
      "title": "Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "SIF001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Suninflam Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 88,
      "start_date": "2025-06-16",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • DeLand, Florida • Tamarac, Florida + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07051629"
    },
    {
      "nct_id": "NCT05844293",
      "title": "Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "FXI"
      ],
      "interventions": [
        {
          "name": "FXI-GalNAc-siRNA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sirnaomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-05-16",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 1,
      "location_summary": "Creve Coeur, Missouri",
      "locations": [
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05844293"
    },
    {
      "nct_id": "NCT06036784",
      "title": "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postbariatric Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "MBX 1416 (Part A)",
          "type": "DRUG"
        },
        {
          "name": "MBX 1416 (Part B)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MBX 1416 (Part C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MBX Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 69,
      "start_date": "2023-09-18",
      "completion_date": "2024-12-05",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06036784"
    },
    {
      "nct_id": "NCT03556228",
      "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Mesothelioma",
        "Esophageal Cancer",
        "Any Solid Tumors Progressed After a Prior Immunotherapy",
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma HNSCC",
        "Salivary Gland Carcinomas",
        "Head and Neck Cancers - Salivary Gland",
        "Head and Neck Cancers - Nasopharyngeal",
        "Head and Neck Cancers - Throat",
        "Small Cell Lung Cancer ( SCLC )",
        "Lung Cancer (Locally Advanced or Metastatic)",
        "Head and Neck Cancers - Tonsils",
        "Head and Neck Cancers Hypopharynx",
        "Head and Neck Cancers Larynx",
        "Head and Neck Cancers Lip",
        "Head and Neck Cancers Nasopharynx",
        "Head and Neck Cancers Oral Cavity",
        "Head and Neck Cancers",
        "Head and Neck Cancers Oropharynx",
        "Head and Neck Cancers Trachea"
      ],
      "interventions": [
        {
          "name": "VMD-928 100 mg Tablet",
          "type": "DRUG"
        },
        {
          "name": "VMD-928 Tablet and Pembrolizumab (200 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VM Oncology, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 242,
      "start_date": "2018-06-08",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03556228"
    },
    {
      "nct_id": "NCT03401671",
      "title": "Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lanadelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-01-15",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-11-09T16:45:26.620Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401671"
    }
  ]
}